COST-EFFECTIVENESS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB IN FIRST-LINE TREATMENT OF ADVANCED MELANOMA IN BELGIUM: ANALYSIS USING 48-MONTH OVERALL SURVIVAL FROM CHECKMATE 067

被引：0
|
作者：
Baker, T. [1 ]
Paly, V. F. [1 ]
Johnson, H. M. [2 ]
Van Campenhout, H. [3 ]
Amadi, A. [2 ]
Chandran, N. [4 ]
Moshyk, A. [5 ]
Kotapati, S. [5 ]
机构：
[1] ICON Plc, New York, NY USA
[2] Bristol Myers Squibb, Uxbridge, Middx, England
[3] Bristol Myers Squibb, Braine Lalleud, Belgium
[4] ICON Plc, Bangalore, Karnataka, India
[5] Bristol Myers Squibb, Lawrenceville, NJ USA
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN142
引用
收藏
页码：S462 / S463
页数：2
相关论文
共 50 条
  • [21] Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma
    Wu, Bin
    Zhang, Qiang
    Sun, Jie
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6
  • [22] Economic Evaluation of Nivolumab Plus Ipilimumab Combination as First-Line Treatment for Patients with Advanced Melanoma in Canada
    Peter L. Quon
    Ying Xiao
    Sonja Sorensen
    Amir Abbas Tahami Monfared
    PharmacoEconomics - Open, 2019, 3 : 321 - 331
  • [23] Economic Evaluation of Nivolumab Plus Ipilimumab Combination as First-Line Treatment for Patients with Advanced Melanoma in Canada
    Quon, Peter L.
    Xiao, Ying
    Sorensen, Sonja
    Monfared, Amir Abbas Tahami
    PHARMACOECONOMICS-OPEN, 2019, 3 (03) : 321 - 331
  • [24] First-line nivolumab plus ipilimumab or chemotherapy versus chemotherapy alone for advanced esophageal cancer: a cost-effectiveness analysis
    Cao, Xueqiong
    Cai, Hongfu
    Li, Na
    Zheng, Bin
    Zheng, Zhiwei
    Liu, Maobai
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 14
  • [25] Overall survival (OS) results from a phase III trial of nivolumab (NIVO) combined with ipilimumab (IPI) in treatment-naive patients with advanced melanoma (CheckMate 067)
    Larkin, James
    Chiarion-Sileni, Vanna
    Gonzalez, Rene
    Rutkowski, Piotr
    Grob, Jean-Jacques
    Cowey, C. Lance
    Lao, Christopher D.
    Schadendorf, Dirk
    Ferrucci, Pier Francesco
    Smylie, Michael
    Dummer, Reinhard
    Hill, Andrew
    Haanen, John
    Maio, Michele
    McArthur, Grant
    Walker, Dana
    Rollin, Linda
    Horak, Christine
    Hodi, F. Stephen
    Wolchok, Jedd D.
    CANCER RESEARCH, 2017, 77
  • [26] COST OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB AS FIRST LINE TREATMENT IN ADVANCED MELANOMA ACROSS VARIOUS EUROPEAN MARKETS
    Ovcinnikova, O.
    Bourhis, F.
    Shah, M.
    Potluri, R.
    Chirita, O.
    Sabater, J.
    Di Rienzo, P.
    VALUE IN HEALTH, 2017, 20 (09) : A426 - A426
  • [27] A COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB FOR THE TREATMENT OF ADVANCED RENAL CELL CARCINOMA IN CANADA
    Lakhdari, K.
    Young, K. C.
    Holdgate, O.
    Doan, J.
    VALUE IN HEALTH, 2018, 21 : S37 - S37
  • [28] Cost-effectiveness of nivolumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma
    Shu, Yamin
    Tang, Ying
    Ding, Yufeng
    Zhang, Qilin
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2023, 122
  • [29] First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data (vol 42, 33, 2024)
    Long, Georgina V.
    Lipson, Evan J.
    Hodi, F. Stephen
    Ascierto, Paolo A.
    Larkin, James
    Lao, Christopher
    Grob, Jean-Jacques
    Ejzykowicz, Flavia
    Moshyk, Andriy
    Garcia-Horton, Viviana
    Zhou, Zheng-Yi
    Xin, Yiqiao
    Palaia, Jennell
    McDonald, Laura
    Keidel, Sarah
    Salvatore, Anthony
    Patel, Divya
    Sakkal, Leon A.
    Tawbi, Hussein
    Schadendorf, Dirk
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (11) : 1398 - 1398
  • [30] COST-EFFECTIVENESS OF NIVOLUMAB VERSUS DACARBAZINE IN FIRST-LINE TREATMENT OF ADVANCED MELANOMA FROM BRAZILIAN PUBLIC HEALTHCARE SYSTEM PERSPECTIVE
    Casagrande Oliveira, A. P.
    Hamza, S.
    Koloszuk, A.
    Marinheiro, P.
    Bernardino, G.
    VALUE IN HEALTH, 2020, 23 : S41 - S41
12345